Prednisone Tablets

Name: Prednisone Tablets

What do I need to tell my doctor BEFORE I take Prednisone Tablets?

  • If you have an allergy to prednisone or any other part of this medicine.
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
  • If you have a herpes infection of the eye.
  • If you have any of these health problems: A fungal infection or malaria infection in the brain.
  • If you have recently spent time in the tropics and have unexplained diarrhea.
  • If you have nerve problems in the eye.
  • If you are breast-feeding or plan to breast-feed.

This is not a list of all drugs or health problems that interact with this medicine (prednisone tablets).

Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.

What are some other side effects of Prednisone Tablets?

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

  • Upset stomach or throwing up.
  • Not able to sleep.
  • Restlessness.
  • Sweating a lot.

These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.

Prednisone Tablets Dosage and Administration

Gastric irritation may be reduced if taken before, during, or immediately after meals or with food or milk.

The maximal activity of the adrenal cortex is between 2 am and 8 am, and it is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocorticoid activity the least when given at the time of maximal activity (am) for single dose administration. Therefore, it is recommended that prednisone be administered in the morning prior to 9 am and when large doses are given, administration of antacids between meals to help prevent peptic ulcers. Multiple dose therapy should be evenly distributed in evenly spaced intervals throughout the day.

Dietary salt restriction may be advisable in patients.

Do not stop taking this medicine without first talking to your doctor. Avoid abrupt withdraw of therapy.

The initial dosage of Prednisone Tablets may vary from 5 mg to 60 mg per day, depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice, while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, PredniSONE should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation, it may be necessary to increase the dosage of PredniSONE for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

Multiple Sclerosis

In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.)

Alternate Day Therapy

Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning. The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children.

The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity. There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight.

The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted during long-term pharmacologic dose corticoid therapy administered in conventional daily divided doses. It would appear, then, that a disturbance in the diurnal cycle with maintenance of elevated corticoid values during the night may play a significant role in the development of undesirable corticoid effects. Escape from these constantly elevated plasma levels for even short periods of time may be instrumental in protecting against undesirable pharmacologic effects.

During conventional pharmacologic dose corticosteroid therapy, ACTH production is inhibited with subsequent suppression of cortisol production by the adrenal cortex. Recovery time for normal HPA activity is variable depending upon the dose and duration of treatment. During this time the patient is vulnerable to any stressful situation. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenocortical suppression for two or more days. Other corticoids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenocortical suppression for 1¼ to 1½ days following a single dose) and thus are recommended for alternate day therapy.

The following should be kept in mind when considering alternate day therapy:

  1. Basic principles and indications for corticosteroid therapy should apply. The benefits of alternate day therapy should not encourage the indiscriminate use of steroids.

  2. Alternate day therapy is a therapeutic technique primarily designed for patients in whom long-term pharmacologic corticoid therapy is anticipated.

  3. In less severe disease processes in which corticoid therapy is indicated, it may be possible to initiate treatment with alternate day therapy. More severe disease states usually will require daily divided high dose therapy for initial control of the disease process. The initial suppressive dose level should be continued until satisfactory clinical response is obtained, usually four to ten days in the case of many allergic and collagen diseases. It is important to keep the period of initial suppressive dose as brief as possible particularly when subsequent use of alternate day therapy is intended. Once control has been established, two courses are available: (a) change to alternate day therapy and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule. Theoretically, course (a) may be preferable.

  4. Because of the advantages of alternate day therapy, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (e.g., patients with rheumatoid arthritis). Since these patients may already have a suppressed HPA axis, establishing them on alternate day therapy may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.

  5. As indicated above, certain corticosteroids, because of their prolonged suppressive effect on adrenal activity, are not recommended for alternate day therapy (e.g., dexamethasone and betamethasone).

  6. The maximal activity of the adrenal cortex is between 2 am and 8 am, and it is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocortical activity the least, when given at the time of maximal activity (am).

  7. In using alternate day therapy it is important, as in all therapeutic situations to individualize and tailor the therapy to each patient. Complete control of symptoms will not be possible in all patients. An explanation of the benefits of alternate day therapy will help the patient to understand and tolerate the possible flare-up in symptoms which may occur in the latter part of the off-steroid day. Other symptomatic therapy may be added or increased at this time if needed.

  8. In the event of an acute flare-up of the disease process, it may be necessary to return to a full suppressive daily divided corticoid dose for control. Once control is again established alternate day therapy may be re-instituted.

  9. Although many of the undesirable features of corticosteroid therapy can be minimized by alternate day therapy, as in any therapeutic situation, the physician must carefully weigh the benefit-risk ratio for each patient in whom corticoid therapy is being considered.

How is Prednisone Tablets Supplied

Prednisone Tablets are available in the following strengths and package sizes:

1 mg (white, round, flat-faced, beveled edge, scored, debossed “5084” on one side and debossed “V” on the reverse side)

  • Bottles of 100                          NDC 0603-5335-21
  • Bottles of 1000                        NDC 0603-5335-32

2.5 mg (white, round, flat-faced, beveled edge, scored, debossed “5085” on one side and debossed “V” on the reverse side)

  • Bottles of 100                          NDC 0603-5336-21

5 mg (white, round, scored, debossed “5094” on one side and debossed “V” on the reverse side)

  • Bottles of 100                          NDC 0603-5337-21
  • Bottles of 1000                        NDC 0603-5337-32
  • Unit-of-Use (21 Tablets)         NDC 0603-5337-15
  • Unit-of-Use (48 Tablets)         NDC 0603-5337-31

10 mg (white, round, scored, debossed “5093” on one side and debossed “V” on the reverse side)

  • Bottles of 100                          NDC 0603-5338-21
  • Bottles of 500                          NDC 0603-5338-28
  • Bottles of 1000                        NDC 0603-5338-32
  • Unit-of-Use (21 Tablets)         NDC 0603-5338-15
  • Unit-of-Use (48 Tablets)         NDC 0603-5338-31

20 mg (peach, round, scored, debossed “5092” on one side and debossed “V” on the reverse side)

  • Bottles of 100                          NDC 0603-5339-21
  • Bottles of 500                          NDC 0603-5339-28
  • Bottles of 1000                        NDC 0603-5339-32

Dispense in a tight, light-resistant container as defined in the USP.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

PRINCIPAL DISPLAY PANEL - 5 mg carton

 

PRINCIPAL DISPLAY PANEL - 20 mg

PREDNISONE 
prednisone tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0603-5335
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PREDNISONE (PREDNISONE) PREDNISONE 1 mg
Inactive Ingredients
Ingredient Name Strength
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
STARCH, CORN  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
SILICON DIOXIDE  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 6mm
Flavor Imprint Code 5084;V
Contains     
Packaging
# Item Code Package Description
1 NDC:0603-5335-21 100 TABLET in 1 BOTTLE, PLASTIC
2 NDC:0603-5335-32 1000 TABLET in 1 BOTTLE, PLASTIC
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040584 12/21/2004
PREDNISONE 
prednisone tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0603-5336
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PREDNISONE (PREDNISONE) PREDNISONE 2.5 mg
Inactive Ingredients
Ingredient Name Strength
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
STARCH, CORN  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
SILICON DIOXIDE  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 6mm
Flavor Imprint Code 5085;V
Contains     
Packaging
# Item Code Package Description
1 NDC:0603-5336-21 100 TABLET in 1 BOTTLE, PLASTIC
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040581 12/21/2004
PREDNISONE 
prednisone tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0603-5337
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PREDNISONE (PREDNISONE) PREDNISONE 5 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
STARCH, CORN  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 6mm
Flavor Imprint Code 5094;V
Contains     
Packaging
# Item Code Package Description
1 NDC:0603-5337-21 100 TABLET in 1 BOTTLE, PLASTIC
2 NDC:0603-5337-32 1000 TABLET in 1 BOTTLE, PLASTIC
3 NDC:0603-5337-15 21 TABLET in 1 BOX, UNIT-DOSE
4 NDC:0603-5337-31 48 TABLET in 1 BOX, UNIT-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040256 07/12/2002
PREDNISONE 
prednisone tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0603-5338
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PREDNISONE (PREDNISONE) PREDNISONE 10 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
STARCH, CORN  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 9mm
Flavor Imprint Code 5093;V
Contains     
Packaging
# Item Code Package Description
1 NDC:0603-5338-21 100 TABLET in 1 BOTTLE, PLASTIC
2 NDC:0603-5338-28 500 TABLET in 1 BOTTLE, PLASTIC
3 NDC:0603-5338-32 1000 TABLET in 1 BOTTLE, PLASTIC
4 NDC:0603-5338-15 21 TABLET in 1 BOX, UNIT-DOSE
5 NDC:0603-5338-31 48 TABLET in 1 BOX, UNIT-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040256 07/12/2002
PREDNISONE 
prednisone tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0603-5339
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PREDNISONE (PREDNISONE) PREDNISONE 20 mg
Inactive Ingredients
Ingredient Name Strength
FD&C YELLOW NO. 6  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
Product Characteristics
Color ORANGE (peach) Score 2 pieces
Shape ROUND Size 10mm
Flavor Imprint Code 5092;V
Contains     
Packaging
# Item Code Package Description
1 NDC:0603-5339-21 100 TABLET in 1 BOTTLE, PLASTIC
2 NDC:0603-5339-28 500 TABLET in 1 BOTTLE, PLASTIC
3 NDC:0603-5339-32 1000 TABLET in 1 BOTTLE, PLASTIC
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040392 02/12/2003
Labeler - Par Pharmaceutical (011103059)
Establishment
Name Address ID/FEI Operations
Generics Bidco II LLC d/b/a Prinston Laboratories 968329537 ANALYSIS(0603-5335, 0603-5336, 0603-5337, 0603-5338, 0603-5339), MANUFACTURE(0603-5335, 0603-5336, 0603-5337, 0603-5338, 0603-5339)
Establishment
Name Address ID/FEI Operations
Generics Bidco II LLC d/b/a Prinston Laboratories 151228897 LABEL(0603-5335, 0603-5336, 0603-5337, 0603-5338, 0603-5339), MANUFACTURE(0603-5335, 0603-5336, 0603-5337, 0603-5338, 0603-5339), PACK(0603-5335, 0603-5336, 0603-5337, 0603-5338, 0603-5339)
Establishment
Name Address ID/FEI Operations
Sharp Corporation 002346625 PACK(0603-5337, 0603-5338)
Establishment
Name Address ID/FEI Operations
Vintage Pharmaceuticals, LLC 825839835 MANUFACTURE(0603-5335, 0603-5336, 0603-5337, 0603-5338, 0603-5339)
Revised: 07/2017   Par Pharmaceutical
(web3)